Skip to content
Parker Institute for Cancer Immunotherapy
Search Close

Nadine Defranoux, PhD

Program Manager



Nadine Defranoux, PhD, joined PICI as program manager in July 2016, shortly after the launch of the institute. She brings over 15 years of experience establishing and leading collaborative research projects and partnerships with pharma and academic centers to tackle complex immune-related problems. Her focus at PICI is to implement and manage antigen discovery programs such as the Tumor nEoantigen SeLection Alliance (aka TESLA), a joint initiative with the Cancer Research Institute (CRI) that regroups over 40 institutions, aimed at optimizing approaches to identify actionable immunogenic neoantigens and ultimately improve personalized therapeutic vaccines.

Prior to joining PICI, Defranoux was associate director for scientific affairs at Myriad Genetics, where she worked on the adoption of the first commercialized multi-biomarker disease activity blood test for patients with rheumatoid arthritis. Prior to that, Defranoux managed global clinical trials in neurodegenerative and neurovascular diseases for an imaging CRO and worked at Entelos, a Biological system modeling company where she led collaborative projects with top-tier pharmaceutical R&D partners. During her nine years at Entelos, she led the development and utilization of large-scale computer models of human immunological diseases including HIV and rheumatoid arthritis designed to gain insight into disease biology, therapeutic approaches and drive decisions concerning drug target identification, prioritization and validation. Her research has led to several patents.

Defranoux received a PhD in microbiology from the Pasteur Institute /Paris VII, France and she completed her post-doctoral training at UCSF in immunology and virology (HIV).